Zobrazeno 1 - 10
of 404
pro vyhledávání: '"Eggermont, Amm"'
Autor:
Eggermont, AMM, Ascierto, PA, Khushalani, NI, Schadendorf, D, Boland, G, Weber, J, Lewis, KD, Johnson, D, Rivalland, G, Khattak, A, Majem, M, Gogas, H, Long, GV, Currie, SL, Chien, D, Tagliaferri, MA, Carlino, MS, Diab, A
Publikováno v:
Future Oncology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Bempegaldesleukin (BEMPEG: NKTR-214) is an immunostimulatory IL-2 cytokine prodrug engineered to deliver a controlled, sustained and preferential IL-2 pathway signal. Nivolumab (NIVO), a PD-L1 inhibitor, has been shown to prolong survival in patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::739d4ac04bcc0a4a655b50961c276ab5
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=7694
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=7694
Publikováno v:
Nature reviews. Clinical oncology, vol 15, iss 9
Eggermont, AMM; Robert, C; & Ribas, A. (2018). The new era of adjuvant therapies for melanoma. NATURE REVIEWS CLINICAL ONCOLOGY, 15(9), 535-536. doi: 10.1038/s41571-018-0048-5. UCLA: Retrieved from: http://www.escholarship.org/uc/item/09t4w25h
Eggermont, AMM; Robert, C; & Ribas, A. (2018). The new era of adjuvant therapies for melanoma. NATURE REVIEWS CLINICAL ONCOLOGY, 15(9), 535-536. doi: 10.1038/s41571-018-0048-5. UCLA: Retrieved from: http://www.escholarship.org/uc/item/09t4w25h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::a73b23c4dc272d478457156f5ce6e9a0
https://escholarship.org/uc/item/09t4w25h
https://escholarship.org/uc/item/09t4w25h
Autor:
Eggermont AMM (AUTHOR), Suciu S (AUTHOR), MacKie R (AUTHOR), Ruka W (AUTHOR), Testori A (AUTHOR), Kruit W (AUTHOR), Punt CJA (AUTHOR), Delauney M (AUTHOR), Sales F (AUTHOR), Groenewegen G (AUTHOR), Ruiter DJ (AUTHOR), Jagiello I (AUTHOR), Stoitchkov K (AUTHOR), Keilholz U (AUTHOR), Lienard D (AUTHOR), EORTC (European Organisation for Research and Treatment of Cancer) Melanoma Group (CORPORATE AUTHOR), Eggermont, Alexander M M1 (AUTHOR), Suciu, Stefan (AUTHOR), MacKie, Rona (AUTHOR), Ruka, Wlodzimierz (AUTHOR)
Publikováno v:
Lancet. 10/1/2005, Vol. 366 Issue 9492, p1189-1196. 8p.
Autor:
Chapman, Pb, Hauschild, A, Robert, C, Haanen, Jb, Ascierto, P, Larkin, J, Dummer, R, Garbe, C, Testori, A, Maio, M, Hogg, D., Lorigan, P, Lebbe, C, Jouary, T, Schadendorf, D, Ribas, A, O'Day, Sj, Sosman, Ja, Kirkwood, Jm, Eggermont, Amm, Dreno, B, Nolop, K, Li, J, Nelson, B, Hou, J, Lee, Rj, Flaherty, Kt, Mcarthur, Ga, BRIM-3 Study Group, Cognetti, F
Publikováno v:
New England Journal of Medicine, 364(26), 2507-2516. Massachussetts Medical Society
BACKGROUND Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation. METHODS We conducted a phase 3 randomized clinic
Autor:
Lienard, D, Eggermont, AMM, Kroon, B, Towse, G, Schmitz, P, Steinmann, G, Rosenkaimer, F, Lejeune, FJ, Schraffordt Koops, H.
Publikováno v:
Melanoma Research, 9(5), 491-502. LIPPINCOTT WILLIAMS & WILKINS
This open, multicentre, randomized phase II trial was conducted to determine the effect of isolated limb perfusion (ILP) with tumour necrosis factor-alpha (TNF alpha) in combination with melphalan with or without interferon-gamma (IFN gamma) in patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=narcis______::ceea5560b743087fbb9dca0cd5cad139
https://research.rug.nl/en/publications/80339b91-f56c-4eb9-b9d0-52767a05b529
https://research.rug.nl/en/publications/80339b91-f56c-4eb9-b9d0-52767a05b529
Autor:
Olieman, AFT, Lienard, D, Eggermont, AMM, Kroon, BBR, Lejeune, FJ, Hoekstra, HJ, Schraffordt Koops, H.
Publikováno v:
Archives of Surgery, 134(3), 303-307. American Medical Association
Archives of Surgery, 134(3), 303-307. AMER MEDICAL ASSOC
Archives of Surgery, 134(3), 303-307. AMER MEDICAL ASSOC
Background: Hyperthermic isolated limb perfusion (HILP) with tumor necrosis factor alpha (TNF-alpha), interferon gamma, and melphalan has proved to be useful in the treatment of recurrent malignant melanoma and of locally advanced soft tissue sarcoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::883330d2f919d4f160f0601e5f2075f6
https://pure.eur.nl/en/publications/ab79321e-4e4b-4660-ac9f-2ea42b7c1e14
https://pure.eur.nl/en/publications/ab79321e-4e4b-4660-ac9f-2ea42b7c1e14
Autor:
Vaglini, M, Suciu, S, Kroon, BBR, Thompson, JF, Gohl, J, Eggermont, AMM, Di Filippo, F, Krementz, ET, Ruiter, D, Lejeune, FJ, Schraffordt Koops, H.
Publikováno v:
Journal of Clinical Oncology, 16, 2906-2912
Journal of Clinical Oncology, 16(9), 2906-2912. American Society of Clinical Oncology
Journal of Clinical Oncology, 16, pp. 2906-2912
Journal of Clinical Oncology, 16(9), 2906-2912. AMER SOC CLINICAL ONCOLOGY
Journal of Clinical Oncology, 16(9), 2906-2912. American Society of Clinical Oncology
Journal of Clinical Oncology, 16, pp. 2906-2912
Journal of Clinical Oncology, 16(9), 2906-2912. AMER SOC CLINICAL ONCOLOGY
Purpose: Patients with primary cutaneous melanoma greater than or equal to 1.5 mm in thickness are at high risk of having regional micrometastases at the time of initial surgical treatment. A phase III international study was designed to evaluate whe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::f4992126537160bd28638990e8b6b80b
http://hdl.handle.net/2066/188817
http://hdl.handle.net/2066/188817
Autor:
Eggermont, AMM, Klausner, JM, Kroon, BBR, Schlag, PM, Lienard, D, vanGeel, AN, Hoekstra, HJ, Meller, [No Value], Nieweg, OE, Kettelhack, C, BenAri, G, Pector, JC, Lejeune, FJ, Schraffordt Koops, H.
Publikováno v:
Annals of Surgery, 224(6), 756-765. LIPPINCOTT WILLIAMS & WILKINS
Objective The objective of the study was to achieve limb salvage in patients with locally advanced soft tissue sarcomas that can only be treated by amputation or functionally mutilating surgery by performing an isolated limb perfusion (ILP) with tumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=narcis______::1b06843188b17a2e369c16aa835e0efb
https://research.rug.nl/en/publications/1150ab09-074a-48a2-b2e2-7a60997b0836
https://research.rug.nl/en/publications/1150ab09-074a-48a2-b2e2-7a60997b0836
Autor:
Eggermont, AMM, Lienard, D, Kroon, BBR, vanGeel, AN, Hoekstra, HJ, Lejeune, FJ, Schraffordt Koops, H.
Publikováno v:
Journal of Clinical Oncology, 14(10), 2653-2665. AMER SOC CLINICAL ONCOLOGY
Purpose: 16 determine the efficacy of isolated limb perfusion (ILP) with tumor necrosis factor-alpha (TNF) in combination with interferon-gamma (IFN) and melphalan as induction therapy to render tumors resectable and avoid amputation in patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=narcis______::dffce30b964e68368bb921ab11adc925
https://research.rug.nl/en/publications/0f55f507-a1b7-4e57-a2ed-455c86b3971a
https://research.rug.nl/en/publications/0f55f507-a1b7-4e57-a2ed-455c86b3971a
Autor:
KLAASE, JM, KROON, BBR, EGGERMONT, AMM, VANGEEL, AN, KOOPS, HS, OLDHOFF, J, LIENARD, D, LEJEUNE, FJ, BERKEL, R, FRANKLIN, HR, HART, AAM
Publikováno v:
European Journal of Cancer, 31A(1), 58-63. ELSEVIER SCI LTD
The aim of this study was to investigate the role of mild hyperthermia (39-40 degrees C) in isolated cytostatic perfusion for patients with recurrent melanoma of the extremities. A total of 218 patients treated with mild hyperthermic perfusion was co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=narcis______::b21cd13eb338f31244051fd20b164926
https://research.rug.nl/en/publications/a8797638-0a81-4dd1-bc34-d65cab5269a2
https://research.rug.nl/en/publications/a8797638-0a81-4dd1-bc34-d65cab5269a2